Pemetinib/pemetinib’s medical insurance reimbursement status and medication warnings

Pemigatinib/Pemigatinib is an innovative drug for the treatment of advanced cholangiocarcinoma with FGFR gene mutations. Although it has shown significant results in clinical treatment, its treatment in terms of medical insurance reimbursement varies from place to place. Due to the diversity of medical insurance policies and insurance plans in various places, whether pemetinib is reimbursable has become a focus of concern for many patients. The current understanding is that although pemetinib has been marketed in China, it is not fully covered by national medical insurance, resulting in patients having to pay for it out of pocket. For specific prices and reimbursement details, patients and their families are advised to consult their local hospital pharmacy or relevant insurance agency.

Cholangiocarcinoma is a highly malignant gastrointestinal tumor, with an incidence rate of approximately3%, and the prognosis is often poor. In recent years, with in-depth research on the pathogenesis of cholangiocarcinoma, especially the revelation of the key role of FGFR2 gene fusion or translocation in intrahepatic cholangiocarcinoma, targeted therapy has gradually become a new treatment strategy. Pemetinib, as an FGFR inhibitor, emerged in this context and showed a survival advantage in second-line treatment of refractory FGFR2 fusion or rearranged cholangiocarcinoma. Therefore, it was approved by the FDA and became the first targeted therapy for cholangiocarcinoma.

However, any medication should be used with caution. Pemetinib is no exception. In animal experiments, researchers found that the drug had potential teratogenic and embryotoxic risks in pregnant rats. Therefore, for female patients who are breastfeeding, breastfeeding should be suspended while receiving pemetinib treatment to ensure the safety of mother and baby. In addition, although the exposure level in humans is relatively low, the abnormal skeletal development caused by pemetinib in some animal experiments cannot be ignored, which suggests that close attention should be paid to its possible impact on the skeletal system during clinical application.